Liposomal doxorubicin is a newer form of chemotherapeutic agents that, due to its own special properties, preferably accumulates in cancer tissue. On the other hand, it shows lower affinity to cardiomyocytes and in this way is less cardiotoxic. As a result of that, there is the possibility to use liposomal form of doxorubicin until disease progression or chemotherapy intolerance in palliative setting, without treatment cessation after reaching the maximum cumulative dose of conventional doxorubicin.
INTRODUCTION
Breast cancer is one of the most frequent types of malignant solid tumours in women [1] . Incidence of breast cancer is growing in Poland, however the mortality rate has been decreasing since 1990s. Currently, over three-fourths of women with breast cancer experience a five-year survival [2] . The last decades have seen a tremendous progress in breast cancer therapy owing to the introduction of monoclonal antibodies (trastuzumab and pertuzumab) [3, 4] , tyrosine kinase inhibitors (lapatinib) [5] and mTOR pathway inhibitors (everolimus) [6] to clinical practice. However, chemotherapy is still the basic treatment for a significant number of breast cancer patients in early and advanced stages [7] [8] [9] .
Anthracyclines are the golden standard of systemic therapy, provided there are no cardiac contraindications [10, 11] . However, the use of anthracyclines is largely limited due to their significant potential cardiotoxicity [12] . For this reason, therapy is continued only until the prescribed cumulative dose is reached.
In the case of patients who have received previous radiation in the chest area or are planned to receive postoperative radiotherapy, the maximum allowable dose of adriamycin or epirubicin is even smaller. The problem of toxicity limiting effectiveness of therapy could be resolved by a cytostatic drug showing similar efficacy to that of anthracyclines and not posing a risk of damage to the heart. The first attempts to create a new chemotherapeutic drug showing such properties were made already in the 1990s [13] . Those efforts resulted in developing new forms of doxorubicin whose molecules were encapsulated in liposomes made of phosphatidylcholine and cholesterol. Their modified structure extended the half-life of the drugs and led to preferential accumulation of the drug in cancerous tissue [14, 15] , thus significantly reducing the risk of cardiotoxicity. However, as a result of the modification, other adverse events increased (e.g. mucositis) or new ones occurred, such as the palmar-plantar erythrodysesthesia that has been seen in patients receiving pegylated liposomal adriamycin [16] . In any case, modified anthracyclines retained their efficacy against tumours [17] . [18]. Due to its additive cardiotoxicity, anthracycline-based chemotherapy has not been broadly used in combination with anti--HER2 therapy outside of clinical settings despite reports on its superior efficacy [19] . Development of adriamycin associated with a lower risk of myocardial damage opened up new possibilities to use more effective drug combinations.
In 2011, the findings of phase 2 clinical trials were published, which evaluated the efficacy and safety profile of a tri-drug neoadjuvant therapy, based on a combination of liposomal doxorubicin with trastuzumab and docetaxel. The clinical response rate was high at 86%, while the cardiac toxicity profile was favourable [20] .
In addition, in case of patients initially treated with radical methods who later develop a metastatic disease, liposomal doxorubicin gives an opportunity to repeat anthracycline-based therapy despite its high cytostatic activity.
In Poland, liposomal doxorubicin may be used in breast cancer therapy only at the stage of metastatic disease. This provides an opportunity to improve the prognosis for patients without exposing them to excessive cardiovascular risk. The patient received a total of 600 mg of liposomal doxorubicin.
CASE PRESENTATION
The patient would not have been able to receive the same amount of conventional doxorubicin because in her case exceeding the threshold amount would dramatically increase the risk of cardiotoxicity.
CONCLUSION
Introduction of new forms of doxorubicin associated with a lower risk of myocardial damage created an opportunity for metastatic breast cancer patients to receive effective treatment.
Such patients may continue therapy until a response is elicited with no severe adverse events involved. Treatment with the liposome-encapsulated cytostatic drug does not need to be interrupted when the maximum lifetime dose is reached, which improves the efficacy of treatment for some patients without exposing them to cardiac complications. This marks a major breakthrough in the therapy of metastatic breast cancer.
